Screener
CURE vs HIBL
Direxion Daily Healthcare Bull 3X Shares vs Direxion Daily S&P 500 High Beta Bull 3X Shares
Key differences
- Over the last 3 years, HIBL has delivered higher annualized returns.
- CURE has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| CURE | HIBL | |
|---|---|---|
| Annual cost (TER) | 0.94% | 0.98% |
| Fund size (AUM) | $138M | $83M |
| Since | 2011 | 2019 |
| Dividend yield | 1.33% | 1.66% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | leveraged | leveraged |
| CAGR 1Y | +31.7% | +242.4% |
| CAGR 3Y | +0.8% | +60.5% |
| CAGR 5Y | +0.7% | +8.7% |
| Sharpe 3Y | 0.14 | 0.96 |
| Volatility 1Y | 42.92% | 66.14% |
| Max drawdown | -69.19% | -88.27% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to CURE and HIBL
Explore further